Providence Health and Services
  Home  |  Health Plans  |  Providers  |  Programs & Services  |  Hospitals & Clinics  |  Health Info  |  Employment  |  Foundations

Site Search
myProvidence:
Login
Register
 
 

 

Publications: Brendan D. Curti M.D.
 

To view related abstracts of these publications, search the PubMed database.

  1. Smith II, J.W., Urba, W.J., Curti, B.D., Elwood, L., Steis, R.G., Janik, J.E., Sharfman, W.H., Miller, L., Fenton, R.G., Conlon, K.C., Sznol, M., Creekmore, S.P., Wells, N., Ruscetti, F.W., Keller, J., Hestdal, K., Shimizu, M., Rossio, J., Alvord, W.G., Oppenheim, J.J., Longo, D.L.:  The toxic and hematologic effects of Interleukin-1 alpha administered in a phase I trial to patients with advanced malignancies.  J. Clin. Oncol. 10:1141-1152, 1992.
  2. Ochoa, J.B., Curti, B., Peitzman, A.B., Simmons, R.L., Billiar, T.R., Hoffman, R., Rault, R., Longo, D.L., Urba, W.J., Ochoa, A.C.:  Increased circulating nitrogen oxides after human tumor immunotherapy correlate with toxic hemodynamic changes.  J. Natl. Cancer Inst. 84:864-867, 1992.
  3. Curti, B.D., Smith II, J.W.  Physiological barriers to drug delivery in tumors.  Clinical Oncology Alert, pp. 70-72, September 1992.
  4. Curti, B.D., Longo, D.L., Ochoa, A., Conlon, K.C., Smith II, J.W., Alvord, W.G., Creekmore, S.P., Fenton, R.G., Gause, B.L., Holmlund, J., Janik, J.E., Ochoa, J., Rice, P.A., Sharfman, W.H., Sznol, M., Urba, W.J.:  Treatment of cancer patients with ex vivo anti-CD3-activated killer cells and interleukin-2.  J. Clin. Oncol. 11:652-660, 1993.
  5. Curti, B.D.  Physical Barriers to Drug Delivery in Tumors.  Crit. Rev. Oncol. Hematol. 14:29-39, 1993.
  6. Curti, B.D., Urba, W.J., Alvord, W.G., Janik, J.E., Smith II, J.W., Madara, K., Longo, D.L.  Interstitial pressure of subcutaneous nodules in melanoma and lymphoma patients:  Changes during treatment.  Cancer Res. 53:2204-2207, 1993.
  7. Smith II, J.W., Longo, D.L., Alvord, W.G., Janik, J.E., Sharfman, W.H., Gause, B.L., Curti, B.D., Creekmore, S.P., Holmlund, J.T., Fenton, R.G., Sznol, M., Miller, L.L., Shimizu, M., Oppenheim, J.J., Fiem, S.J., Hursey, J.C., Powers, G.C., Urba, W.J.  The effects of treatment with interleukin-1 alpha on platelet recovery after high-dose carboplatin.  N. Engl. J. Med. 328:756-761, 1993.
  8. Curti, B.D.  Adoptively transferred anti-CD3-activated T cells for human tumor immunotherapy (Reply to a letter to the Editor).  J. Clin. Oncol. 11:1836-1837, 1993.
  9. Curti, B.D., Longo, D.L.  Specific oncologic issues in the critically ill, in Parrillo, J.E. and Bone, R.C. (Eds.):  Critical Care Medicine:  Principles of Diagnosis and Management.  St. Louis, Mosby-Year Book, 1994, pp. 1345-1362.
  10. Curti, B.D., Smith II, J.W.  Interleukin-1 in the treatment of cancer.  Pharmac. Ther. 65:291-302, 1995.
  11. Zea, A.H., Curti, B.D., Longo, D.L., Alvord, W.G., Strobl, S.L., Mizoguchi, H., Creekmore, S.P., O'Shea, J.J., Powers, G.C., Urba, W.J., Ochoa, A.C.  Alterations in T cell receptor and signal transduction molecules in melanoma patients.  Clin. Cancer Res. 1:1327-1335, 1995.
  12. Sharfman, W.H., Urba, W.J., Smith II, J.W., Janik, J.E., Curti, B.D., Gause, B.L., Holmlund, J.T., Steis, R.G., Beauchamp, A.E., Longo, D.L.  Phase I/II Trial of 5-fluorouracil, leucovorin, zidovudine, and dipyridamole for patients with metastatic colorectal cancer, renal cell carcinoma, and malignant melanoma.  Int. J. Oncol. 6:579-583, 1995.
  13. Curti, B.D.  Physical barriers to drug delivery in tumors.  In Chabner, B.A. and Longo, D.L. (Eds.):  Cancer Chemotherapy and Biotherapy (second edition).  Philadelphia, J.B. Lippincott, 1996, pp. 709-719.
  14. Curti, B.D., Urba, W.J., Longo, D.L., Janik, J.E., Sharfman, W.H., Miller, L.L., Cizza, G., Shimizu, M., Oppenheim, J.J., Alvord, W.G., Smith II, J.W.  Endocrine effects of IL-1alpha and beta administered in a phase I trial to patients with advanced cancer.  J. Immunother. 19:142-148, 1996.
  15. Curti, B.D.  Adoptive immunotherapy.  In Pinedo, H.M., Longo, D.L., and Chabner, B.A. (Eds.):  Cancer Chemotherapy and Biological Response Modifiers, Annual 16.  Amsterdam, Elsevier, 1996, pp. 274-284.
  16. Janik, J.E., Miller, L.L., Longo, D.L., Powers, G.C., Urba, W.J., Kopp, W.C., Gause, B.L., Curti, B.D., Fenton R.G., Oppenheim, J.J., Conlon, K.C., Holmlund, J.T., Sznol, M., Sharfman, W.H., Steis, R.G., Creekmore, S.P., Alvord, W.G., Beauchamp, A.E., Smith II, J.W.  Phase II trial of interleukin 1alpha and indomethacin in treatment of metastatic melanoma.  J. Natl. Cancer Inst. 88:44-49, 1996.
  17. Curti, B.D., Longo, D.L.  A brief history of the immunologic thinking: Is it time for yin and yang?  In Bellomo, N., and Adam, J.A.. (Eds.): Models of Tumor and Immune System Dynamics, Selected  Surveys.  Boston, Birkhauser, 1996, pp. 1-13.
  18. Curti, B.D., Ochoa, A.C., Urba, W.J., Alvord, W.G., Kopp, W.C., Powers, G., Hawk, C., Creekmore, S.P., Gause, B.L., Janik, J.E., Holmlund, J.T., Kremers, P., Fenton, R.G., Miller, L., Sznol, M., Smith II, J.W., Sharfman, W.H., Longo, D.L.  The influence of interleukin-2 regimens on circulating populations of lymphocytes after adoptive transfer of anti-CD3-stimulated T cells: Results from a phase I trial in cancer patients.  J. Immunother. 19:296-308, 1996.
  19. Fenton, R.G., Steis, R.G., Madara, K., Zea, A.H., Ochoa, A.C., Janik, J.E., Smith II, J.W., Gause, B.L., Sharfman, W.H., Urba, W.J., Hanna, M.G., DeJager, R.L., Coyne, M.X., Crouch, R.D., Gray, P., Beveridge, J., Creekmore, S.P., Holmlund, J., Curti, B.D., Sznol, M., Longo, D.L.  A phase I randomized study of subcutaneous adjuvant IL-2 in combination with an autologous tumor vaccine in patients with advanced renal cell carcinoma.  J. Immunother. 19:364-373, 1996.
  20. Curti, B.D.  The cancer patient.  In Parrillo, J.E. and Bone, R.C. (Eds.):  Current Therapy in Critical Care Medicine.  St. Louis, Mosby-Year Book, 1997, pp. 368-373.
  21. Saxton, M.L., Longo, D.L., Wetzel, H.E., Tribble, H., Alvord, W.G., Kwak, L.W., Leonard, A.S., Dansky-Ullmann, C., Curti, B.D., Ochoa, A.C.  Adoptive transfer of anti-CD3-activated CD4+ T cells plus cyclophosphamide and liposome-encapsulated IL-2 cure murine MC-38 and 3LL tumors, and establish tumor-specific immunity.  Blood 89:2529-2536, 1997.
  22. Curti, B.D.  Adoptive immunotherapy.  In Pinedo, H.M., Longo, D.L., and Chabner, B.A. (Eds.):  Cancer Chemotherapy and Biological Response Modifiers, Annual 17.  Amsterdam, Elsevier, 1997.
  23. Janik, J.E., Curti, B.D., Considine, R.V., Rager, H.C., Powers, G., Alvord, W.G., Smith, J.W., Gause, B.L., Kopp, W.C.  IL-1 alpha increases serum leptin concentrations in man.  J. Clin. Endocrinol. 82:3084-3086, 1997.
  24. Vortmeyer, A.O., Kingma, D.W., Fenton, R.G., Curti, B.D., Jaffe, E.S., Duray, P.H. Hepatobiliary lymphoepithelioma-like carcinoma associated with Epstein-Barr virus - A case report.  Am. J. Clin. Pathol. 109:90-95, 1998.
  25. Yoe, J., Gause, B.L., Curti, B.D., Longo, D.L., Bagg, A., Kopp, W.C., Janik, J.E.: Development of rheumatoid arthritis after treatment of large granular lymphocyte leukemia with deoxycoformycin.  Am J. Hematol.  57:253-257, 1998.
  26. Gause, B.L., Sharfman, W.H., Janik, J.E., Curti, B.D., Steis, R.G., Urba, W.J., Smith II, J.W., Longo, D.L.:  A phase II study of carboplatin, cisplatin, interferon alpha and tamoxifen for patients with metastatic melanoma.  Cancer Investigation 16:374-380, 1998.
  27. Curti, B.D., Ochoa, A.C., Powers, G.C., Kopp, W.C., Alvord, W.G., Janik, J.E., Gause, B.L., Dunn, B., Kopreski, M., Fenton, R.G., Zea, A.H., Dansky Ullmann, C., Strobl, S., Harvey, L., Nelson, E., Sznol, M., Longo, D.L.  A phase I trial of anti-CD3-stimulated CD4+ T cells given with infusional interleukin-2 and cyclophosphamide to patients with advanced cancer.  J. Clin. Oncol.. 16:2752-2760, 1998.
  28. Miller, L.L., Korn, E.L., Stevens, D.S., Janik, J.E., Gause, B.L., Kopp, W.C., Holmlund, J.T., Curti, B.D., Sznol, M., Smith II, J.W., Donnegan, S.E., Watson, T.M., Garrison, L., Hanna, R., Longo, D.L.  Abrogation of the hematological and biological activities of the novel interleukin-3/granulocyte-macrophage colony-stimulating factor fusion protein PIXY321 by neutralizing anti-PIXY321 antibodies in cancer patients receiving high-dose carboplatin: results of a phase I study.  Blood. 93:3250-3258, 1999.
  29. Janik, J.E., Miller, L.L., Kopp, W.C., Stevens, D., Kostboth, P., Curti, B.D., Conlon, K.C., Dunn, B.K., Donegan, S.E., Alvord, W.G., Ulrich, R., Gause, B.L., Longo, D.L.  Treatment with tumor necrosis factor alpha and granulocyte-macrophage colony stimulating factor increases epidermal Langerhans cell numbers in cancer patients.  Clin Immunol.  93:209-221, 1999. 
  30. Curti, B.D.  Adoptive immunotherapy.  In Pinedo, H.M., Longo, D.L., and Chabner, B.A. (Eds.):  Cancer Chemotherapy and Biological Response Modifiers, Annual 18.  Amsterdam, Elsevier, 1999.
  31. Arun, B., Curti, B.D., Longo, D.L., Stevens, D., Alvord, W.G., Gause, B.L., Watson, T., Kopp, W.C., Janik, J.E.  Elevations in serum soluble interleukin-2 receptor levels predict relapse in patients with hairy cell leukemia.  Cancer J. Scientific American, 6:21-24, 2000.
  32. Curti, B.D.  Physical barriers to drug delivery in tumors.  In  Chabner, B.A. and Longo, D.L. (Eds.):  Cancer Chemotherapy and Biotherapy (third edition).  Philadelphia, J.B. Lippincott, 2001.
  33. Janik, J.E., Miller, L.L., Korn, E.L., Stevens, D., Curti, B.D., Smith II, J.W., Sznol, M., Conlon, K.C., Sharfman, W., Urba, W.J., Gause, B.L., Longo, D.L.  A prospective randomized phase II trial of GM-CSF priming to prevent topotecan-induced neutropenia in chemotherapy-naive patients with malignant melanoma or renal cell carcinoma.  Blood, 97:1942-1946, 2001.
  34. Longo, D.L., Duffey, P.L., Gribben, J.G., Jaffe, E.S., Curti, B.D., Gause, B.L., Janik, J.E., Bramen, V.M., Esseltine, D., Wilson, W.H., Kaufman, D., Wittes, R.E., Nadler, L.M., Urba, W.J.  Combination chemotherapy followed by a recombinant immunotoxin (anti-B4-blocked ricin) in patients with indolent lymphoma: results of a phase II study.  Cancer J. Sci. Am., 6:146-150, 2001.
  35. Curti, B.D., Longo, D.L.  Specific oncologic issues in the critically ill, in Parrillo, J.E. and Bone, R.C. (Eds.):  Critical Care Medicine:  Principles of Diagnosis and Management.  2nd Ed.   St. Louis, Mosby-Year Book, 2002.
  36. Curti, B.D. Renal cell carcinoma.  JAMA, 292(1):97-100, 2004.
  37. Ma, J., Poehlein, C.H., Jensen, S.M., LaCelle, M.G., Moudgil, T.M., Rüttinger, D., Haley, D., Goldstein, M.J., Smith III, J.W., Curti, B., Ross, H., Walker, E., Hu, H.M., Urba, W.J, Fox, B.A. Manipulating the host response to autologous tumour vaccines, in Brown, F., and Petricciani, J. (Eds.):  Development of Therapeutic Cancer Vaccines. Dev. Biol. Basel, Karger, 116:93-107, 2004.
  38. Motzer, R.J., Rini, B.I., Bukowski, R.M., Curti, B.D., George, D.J., Hudes, G.R., Redman, B.G., Margolin, K.A., Merchan, J.R., Wilding, G., Ginsberg, M.S., Bacik, J., Kim, S.T., Baum, C.M., Michaelson, M.D. Sunitinib in patients with metastatic renal cell carcinoma. JAMA, 295:2516-2524, 2006.
  39. Curti, B.D. Immunomodulatory and antitumor effects of interleukin-21 in patients with renal cell carcinoma. Expert Rev. Anticancer Ther., 6(6):905-909, 2006.
  40. Morris, N.P., Peters, C., Montler, R., Hu, H.M., Curti, B.D., Urba, W.J., Weinberg, A.D. Development and characterization of recombinant human Fc:OX40L fusion protein linked via a coiled-coil trimerization domain. Mol. Immunol., 44(12):3112-3121, 2007.
Home | myProvidence
Notice of Privacy Practices
Site Map | Contact | FAQ


Terms of Use and Privacy Policy | Disclaimer